SCID Awaiting Transplant: Treating the Vaccine, Not Just the Diagnosis
A five-month-old girl with newly diagnosed SCID, already shedding vaccine-strain rotavirus from a dose she received before anyone knew she couldn’t clear it. The dispute is whether to condition her for transplant now or bring the infection under control first — when real evidence says full clearance may require the very transplant everyone is debating whether to delay.
Nadia F. is five months old, the youngest of three girls in a family that moved to Ohio eighteen months ago when her father took a warehouse-management job. She received her scheduled two-month rotavirus vaccine at a normal well-child visit, the same as her older sisters had at that age, and nobody had reason to think otherwise until she stopped gaining weight and developed diarrhea that never resolved. Her sisters, both healthy, had the identical vaccine on the identical schedule with no complications — a fact her parents keep returning to, since nothing about her pregnancy or newborn period looked different from theirs. The workup that followed — profound lymphopenia, absent T-cell receptor excision circles on a retrospective dried-blood-spot test, a confirmed pathogenic variant — diagnosed severe combined immunodeficiency five weeks after that single oral vaccine dose she should never have received.
Stool RT-PCR confirms rotavirus, and gene sequencing matches it to the vaccine strain, not a wild-type infection — the same pattern described in Patel et al., 2010, New England Journal of Medicine, in three infants whose SCID diagnosis was made only after an ordinary immunization triggered a persistent infection their T cells couldn't clear. That paper's real, load-bearing detail is what makes this decision hard rather than simple: in every comparable published case, viral shedding stopped only once the patient's own T-cell immunity was reconstituted — which means the treatment everyone agrees will eventually clear this infection is also the one whose safety profile worsens when it's started on top of an already-inflamed gut and five weeks of poor growth. She has dropped from the 40th percentile for weight to the 8th over that span, a decline steep enough that her team is treating nutritional stabilization as its own clinical problem, not just a symptom that will resolve once the underlying question is settled.
Bridging care while the donor search runs
Every week we wait for a fully matched donor is a week she carries an active enteric infection with a T-cell system that cannot touch it. Kaplon et al., 2015, Pediatric Infectious Disease Journal, followed rotavirus vaccine-strain shedding in SCID infants and found viral clearance tracked immune reconstitution, not antiviral therapy — the same pattern reported in other published SCID cases with this exact complication. I want to move toward conditioning on the fastest safe donor timeline we actually have, rather than hold for a clearance that the literature says won't come first.
I agree the infection likely won't fully clear until she's engrafted — that part isn't in dispute. What I'd push back on is starting conditioning today, on a gut that's already inflamed and a baby who's dropped thirty-two percentile points in five weeks. Rossignol et al.'s randomized, placebo-controlled trial found nitazoxanide reduces rotavirus disease duration in hospitalized children, even though that trial wasn't done in SCID infants specifically, and buying two to three weeks of nutritional stabilization before conditioning begins is not the same as waiting for full viral clearance.
Wanting to move fast isn't the same as it being safe to move fast on this particular gut, today.
Neither of you actually needs the other to wait. Start nitazoxanide and push caloric support now, in parallel with the unrelated-donor search that's already running — none of that delays donor identification by a single day. Immunoglobulin doesn't meaningfully help here; IgG has poor penetration into gut mucosa, so more of it won't touch a rotavirus infection the way it protects against systemic bacterial disease. The actual decision point isn't today — it's the day a donor is identified, when we reassess her nutritional and inflammatory status against whatever conditioning regimen that donor match calls for.
Nitazoxanide and enhanced caloric support started the same day, alongside the already-running unrelated donor search — no element of the infectious-disease physician's plan delayed the transplant timeline by a single day, which resolved most of the practical disagreement. Weight stabilized within ten days; stool rotavirus remained detectable but at a lower viral load on repeat testing three weeks later.
Not agreed: whether nitazoxanide meaningfully changed that trajectory or whether she would have stabilized on supportive care and time alone — the infectious disease physician credits the drug, the transplant physician remains convinced engraftment will be the actual clearance event whenever a donor is found, and neither treats the other's view as wrong given the absence of a controlled comparison in this population.